My Nasal Cannula Won’t Keep Me From Canoodling With My Love

Cancer-suppressing Molecule May Be PF Therapeutic Target

The levels of a cancer-suppressing molecule called microRNA-326 (miR-326) are reduced significantly in the lungs of a mouse model of silica-induced pulmonary fibrosis (PF), a study shows. Increasing the levels of miR-326 in these mice lessened lung scarring (fibrosis) and suppressed the production of pro-fibrotic molecules, highlighting miR-326 as a…

First Healthy Volunteer Dosed in Trial Testing ISM001-055 for IPF

The first healthy volunteer has been dosed in a trial evaluating ISM001-055, Insilico Medicine’s artificial intelligence (AI)-discovered therapy candidate for idiopathic pulmonary fibrosis (IPF). “We are very pleased to see Insilico Medicine’s first antifibrotic [treatment] candidate entering into the clinic,” Feng Ren, PhD, Insilico’s chief strategy officer, said…

Cudetaxestat for IPF Found Safe in Phase 1 Trial of Healthy Volunteers

Cudetaxestat (BLD-0409), an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed favorable safety and tolerability in a Phase 1 trial of healthy volunteers. Developed by Blade Therapeutics, cudetaxestat is designed to block the activity of an enzyme called autotaxin that produces a pro-scarring (fibrotic) signaling molecule. This enzyme commonly…

Reflecting on Another Birthday With IPF

A doctor once told me he wasn’t sure I’d survive until my 30th birthday. If I did, I’d likely be dependent on supplemental oxygen, unlike any other young adult I knew at the time. This week, I turned 34. Reflecting on my nearly six years with idiopathic pulmonary fibrosis (IPF)…

Chiesi Acquires Zampilimab, Antibody to Potentially Treat IPF

Chiesi announced it has secured from UCB rights to zampilimab, a monoclonal antibody being investigated to treat idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Under the agreement, Chiesi acquired global exclusive rights to develop and manufacture the potential antifibrotic therapy, and to market it should it be approved.

Nuformix’s NXP002 for IPF Shows Promise in Preclinical Studies

NXP002, Nuformix’s experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), achieves significant levels in the lungs and lowers the production of molecules that promote scarring, according to preclinical studies involving rats, the company announced. “We’re delighted with the positive readout of this data so far and it further…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums